Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.66 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840091 | 0.90 | ADRB2 (0.82) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3189983 | 0.90 | ADRB2 (0.60) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL3190008 | 0.90 | ADRB2 (0.60) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL3176536 | 0.90 | ADRB2 (0.81) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3189995 | 0.90 | ADRB2 (0.60) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL3195499 | 0.90 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3194339 | 0.89 | ADRB2 (0.82) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3186154 | 0.88 | ADRB2 (0.74) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3197801 | 0.87 | ADRB2 (0.81) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3191849 | 0.84 | ADRB2 (0.64) | ADRB2ADRB1ADRB3DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662815-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2010-02-16 | — | — | US | claimed |
| US-20080113981-A1 | Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-05-15 | — | — | US | claimed |
| US-7317023-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | claimed |
| US-20060019991-A1 | Diaryl ether beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-01-26 | — | — | US | claimed |
| US-7662815-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080113981-A1 | Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-05-15 | — | — | US | disclosed |
| US-7317023-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060019991-A1 | Diaryl ether beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019991-A1 | Diaryl ether beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 5/4885 |
| US-20080113981-A1 | Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.